文献速递类风湿关节炎

抗CD40抗体BI 655064治疗活动性类风湿关节炎的IIa期研究

Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study.
PubMed 文献 · Ann Rheum Dis · 2019-03-22

这项随机、双盲、安慰剂对照IIa期研究纳入67例甲氨蝶呤应答不足的活动性类风湿关节炎患者,每周皮下注射BI 655064 120mg或安慰剂12周。第12周主要终点ACR20未达到统计学显著差异(68.2% vs 45.5%,p=0.064),但BI 655064显著改变CD40-CD40L通路相关标志物且安全性良好。

要点

  • MTX-IR活动性RA患者中BI 655064未达到主要疗效终点ACR20。
  • BI 655064降低炎症、骨吸收标志物及自身抗体和活化B细胞亚群。
  • 未发生与研究药物相关的严重不良事件或血栓栓塞事件。

核心结论

  • BI 655064阻断CD40-CD40L通路虽引起临床和生物学参数显著变化,但在这项小型IIa期研究中未证实临床疗效。

研究设计与样本

  • 随机、双盲、安慰剂对照IIa期研究,67例MTX-IR活动性RA患者随机接受每周皮下BI 655064 120mg(n=44)或安慰剂(n=23)治疗12周。

主要发现

  • 第12周BI 655064组ACR20应答率68.2%,安慰剂组45.5%(p=0.064),主要终点未达到。
  • 贝叶斯分析显示观察到差异大于35%的后验概率为42.9%。
  • BI 655064与CD40-CD40L通路相关标志物更大变化相关,包括白细胞介素-6、基质金属蛋白酶-3、核因子κB受体活化因子配体降低。
  • BI 655064降低自身抗体(IgG RF、IgM RF、IgA RF)浓度及CD95+活化B细胞亚群。
  • 未发生与BI 655064治疗相关的严重不良事件或血栓栓塞事件,报告的不良事件主要为轻度。

关键数值与推荐

  • 主要终点为第12周达到美国风湿病学会20%改善标准(ACR20)的患者比例。

临床怎么用

  • BI 655064在MTX-IR活动性RA中未显示显著临床疗效,不支持进一步作为单药推进临床开发。

局限性

  • 本研究为小型IIa期研究,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the safety, efficacy and therapeutic mechanism of BI 655064, an antagonistic anti-CD40 monoclonal antibody, in patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX-IR). METHODS: In total, 67 patients were randomised to receive weekly subcutaneous doses of 120 mg BI 655064 (n=44) or placebo (n=23) for 12 weeks. The primary endpoint was the proportion of patients who achieved 20% improvement in American College of Rheumatology criteria (ACR20) at week 12. Safety was assessed in patients who received at least one dose of study drug. RESULTS: At week 12, the primary endpoint was not met, with 68.2% of patients treated with BI 655064 achieving an ACR20 vs 45.5% with placebo (p=0.064); using Bayesian analysis, the posterior probability of seeing a difference greater than 35% was 42.9%. BI 655064 was associated with greater changes in CD40-CD40L pathway-related markers, including reductions in inflammatory and bone resorption markers (interleukin-6, matrix metalloproteinase-3, receptor activator of nuclear factor-κB ligand), concentration of autoantibodies (immunoglobulin [Ig]G rheumatoid factor [RF], IgM RF, IgA RF) and CD95+ activated B-cell subsets. No serious adverse events (AEs) related to BI 655064 treatment or thromboembolic events occurred; reported AEs were mainly of mild intensity. CONCLUSION: Although blockade of the CD40-CD40L pathway with BI 655064 in MTX-IR patients with RA resulted in marked changes in clinical and biological parameters, including reductions in activated B-cells, autoantibody production and inflammatory and bone resorption markers, with a favourable safety profile, clinical efficacy was not demonstrated in this small phase IIa study. TRIAL REGISTRATION NUMBER: NCT01751776.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Visvanathan S, Daniluk S, Ptaszyński R, et al. Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study. Ann Rheum Dis. 2019. PMID: 30902820. doi:10.1136/annrheumdis-2018-214729

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。